1 results found.

Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage Clinical Trial using ofatumumab; bendamustine hydrochloride; bortezomib; laboratory biomarker analysis; positron emission tomography with radiolabeled targeting agents; fludeoxyglucose F 18

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib (NSC # 681239, IND # 58443) and Bendamustine in Patients With Untreated Follicular Lymphoma.
ofatumumab; bendamustine hydrochloride; bortezomib; laboratory biomarker analysis; positron emission tomography with radiolabeled targeting agents; fludeoxyglucose F 18